Table 1.
Age/sex | Comorbid conditions | Decitabine | EF 1a | Biomarker | Testb | EF 2c | EF Δd | |
---|---|---|---|---|---|---|---|---|
De et al. [6] (2012) | 75 yrs/M | DM type II, DVT | 2 cycles | 35% | BNP: 259 | Coronary angiogram | 50% (after 7 days) | Yes |
Our patient | 71 yrs/F | HTN, Hep B, hypothyroidism | 10 cycles | 28% | Pro-BNP: 517 | Nuclear stress test | 28% (after 4 weeks) but with improvement in strain | No |
aBaseline left ventricular ejection fraction. bTest to rule out coronary artery disease. cRepeat left ventricular ejection fraction. dReversibility of ejection fraction. Note: both patients received decitabine as part of treatment for acute myeloid leukemia. Abbreviations: BNP: brain natriuretic peptide; DM: diabetes mellitus; DVT: deep vein thrombosis; EF: ejection fraction; HTN: hypertension; Hep B: hepatitis B; BNP units: pg/ml.